206 related articles for article (PubMed ID: 20923426)
1. Lipid peroxidation in patients with schizophrenia.
Dietrich-Muszalska A; Kontek B
Psychiatry Clin Neurosci; 2010 Oct; 64(5):469-75. PubMed ID: 20923426
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of aripiprazole and selected antipsychotic drugs on lipid peroxidation in plasma.
Dietrich-Muszalska A; Kolińska-Łukaszuk J
Psychiatry Clin Neurosci; 2018 May; 72(5):329-336. PubMed ID: 29280533
[TBL] [Abstract][Full Text] [Related]
3. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
4. Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro.
Dietrich-Muszalska A; Kontek B; Rabe-Jabłońska J
Neuropsychobiology; 2011; 63(4):197-201. PubMed ID: 21422766
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics.
Padurariu M; Ciobica A; Dobrin I; Stefanescu C
Neurosci Lett; 2010 Aug; 479(3):317-20. PubMed ID: 20561936
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
7. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
8. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients.
Al-Chalabi BM; Thanoon IA; Ahmed FA
Neuropsychobiology; 2009; 59(1):8-11. PubMed ID: 19221442
[TBL] [Abstract][Full Text] [Related]
9. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics.
Zhang XY; Tan YL; Cao LY; Wu GY; Xu Q; Shen Y; Zhou DF
Schizophr Res; 2006 Jan; 81(2-3):291-300. PubMed ID: 16309894
[TBL] [Abstract][Full Text] [Related]
10. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.
Yasui-Furukori N; Sato Y; Furukori H; Saito M; Nakagami T; Kaneko S
J Clin Psychiatry; 2009 Jan; 70(1):95-100. PubMed ID: 19026267
[TBL] [Abstract][Full Text] [Related]
11. Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia.
Vidović B; Milovanović S; Dorđević B; Kotur-Stevuljević J; Stefanović A; Ivanišević J; Miljković M; Spasić S; Stojanović D; Pantović M
Psychiatr Danub; 2014 Sep; 26(3):205-13. PubMed ID: 25191766
[TBL] [Abstract][Full Text] [Related]
12. Free radicals, antioxidant defense systems, and schizophrenia.
Wu JQ; Kosten TR; Zhang XY
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():200-6. PubMed ID: 23470289
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.
Kinon BJ; Liu-Seifert H; Ahl J; Ahmed S; Baker RW
Ann N Y Acad Sci; 2004 Dec; 1032():295-6. PubMed ID: 15677433
[TBL] [Abstract][Full Text] [Related]
14. Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients.
Ingole S; Belorkar NR; Waradkar P; Shrivastava M
Indian J Physiol Pharmacol; 2009; 53(1):47-54. PubMed ID: 19810576
[TBL] [Abstract][Full Text] [Related]
15. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
[TBL] [Abstract][Full Text] [Related]
16. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.
Konarzewska B; Wołczyński S; Szulc A; Galińska B; Popławska R; Waszkiewicz N
Psychoneuroendocrinology; 2009 Jan; 34(1):129-39. PubMed ID: 18838228
[TBL] [Abstract][Full Text] [Related]
17. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.
Savina I; Beninger RJ
Schizophr Res; 2007 Aug; 94(1-3):128-38. PubMed ID: 17560766
[TBL] [Abstract][Full Text] [Related]
18. Thiobarbituric acid reactive substances in the cerebrospinal fluid in schizophrenia.
Skinner AO; Mahadik SP; Garver DL
Schizophr Res; 2005 Jul; 76(1):83-7. PubMed ID: 15927801
[TBL] [Abstract][Full Text] [Related]
19. Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial.
Takahashi H; Yoshida K; Ishigooka J; Higuchi H
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1067-72. PubMed ID: 16759777
[TBL] [Abstract][Full Text] [Related]
20. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia.
Akerele E; Levin FR
Am J Addict; 2007; 16(4):260-8. PubMed ID: 17661193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
